Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: A sequential study in 42 patients

Experimental Hematology

Volumn 31, Issue 3, 2003, Pages 204-210

  Hernández Boluda, Juan Carlos ^a   Cervantes, Francisco ^a   Colomer, Dolors ^a   Vela, Mari Carmen ^a   Costa, Dolors ^a   Paz, María Fe ^b   Esteller, Manel ^b   Montserrat, Emilio ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b Hospital Infantil Universitario Niño Jesús   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; BLAST CELL CRISIS; CHROMOSOME 16; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DONOR; EXON; FEMALE; GENE DELETION; GENE INACTIVATION; GENE LOCUS; GENOME; HOMOZYGOSITY; HUMAN; HUMAN CELL; LEARNING; MALE; MEDICAL ASSESSMENT; METHYLATION; MYELOPROLIFERATIVE DISORDER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; SAMPLE; STATISTICAL SIGNIFICANCE;

EID: 17744401777     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(02)01075-5     Document Type: Article

References (37)

1. Sawyers C.L. Chronic myeloid leukemia. N Engl J Med. 340:1999;1330-1340.
2. Cervantes F., Rozman M., Rosell J., Urbano-Ispizua A., Montserrat E., Rozman C. A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia. Br J Haematol. 76:1990;27-32.
3. bcr/abl gene of Philadelphia chromosome. Science. 247:1990;824-830.
4. Anastasi J., Feng J., LeBeau M.M., Larson R.A., Rowley J.D., Vardiman J.W. The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. Leukemia. 9:1995;628-633.
5. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., Kantarjian H.M. The biology of chronic myeloid leukemia. N Engl J Med. 341:1999;164-172.
6. Drexler H.G. Review of alterations of the cyclin-dependent kinase INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 12:1998;845-859.
7. ARF in hematological malignancies. Leukemia. 13:1999;1760-1769.
8. Quelle D.E., Zindy F., Ashmun R.A., Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 83:1995;993-1000.
9. Sill H., Goldman J.M., Cross C.P. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood. 85:1995;2013-2016.
10. Serra A., Gottardi E., Della Ragione F., Saglio G., Iolascon A. Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. Br J Haematol. 91:1995;625-629.
11. INK4A characterize the major types of hematological malignancies. Cancer Res. 57:1997;837-841.
12. Iolascon A., Della Ragione F., Giordani L., Serra A., Saglio G., Faienza M.F. Expression of cell cycle regulatory genes in chronic myelogenous leukemia. Haematologica. 83:1998;771-777.
13. Kantarjian H.M., Dixon D., Keating M.J.et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 61:1988;1441-1446.
14. Cervantes F., López-Guillermo A., Bosch F., Terol M.J., Rozman C., Montserrat E. An assessment of the clinicohaematological criteria for the accelerated phase of chronic myeloid leukaemia. Eur J Haematol. 57:1996;286-291.
15. Hernández-Boluda J.C., Cervantes F., Alvarez A., Costa D., Montserrat E. Single-agent therapy with oral mercaptopurine for nonlymphoid blast crisis of chronic myeloid leukemia. Ann Hematol. 80:2001;516-520.
16. Cervantes F., Villamor N., Esteve J.et al. 'Lymphoid' blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. Br J Haematol. 100:1998;123-128.
17. nd edition. New York, 1989.
18. Mori N., Morosetti R., Lee S.et al. Allelotype analysis in the evolution of chronic myelocytic leukemia. Blood. 90:1997;2010-2014.
19. INK4A deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. Blood. 97:2001;572-574.
20. Pinyol M., Hernández L., Martínez A.et al. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol. 156:2000;1987-1996.
21. INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia. 14:2000;1727-1735.
22. waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood. 89:1997;272-280.
23. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR. a novel PCR assay for methylation status of CpG islands Proc Natl Acad Sci U S A. 93:1996;9821-9826.
24. Kaplan G., Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 53:1985;457-463.
25. 2/E in the logrank test for survival data on tumor incidence data. Biometrics. 29:1973;579-584.
26. Neubauer A., He M., Schmidt C.A., Huhn D., Liu E.T. Genetic alterations in the p53 gene in the blast crisis of chronic myelogeneous leukemia. analysis by polymerase chain based techniques Leukemia. 4:1993;593-600.
27. McCarthy D.M., Rassool F.V., Goldman J.M., Graham S.V., Birnie G.D. Genomic alterations involving the c-myc proto-oncogene locus during the evolution of a case of chronic granulocytic leukaemia. Lancet. 2:1984;1362-1365.
28. Ogawa S., Kurokawa M., Tanaka T.et al. Increased evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia. Leukemia. 10:1996;788-794.
29. LeMaistre A., Lee M.S., Talpaz M.et al. Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood. 73:1989;889-891.
30. Gaidano G., Serra A., Guerrasio A., Rege-Cambrin G., Mazza U., Saglio G. Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia. Ann Hematol. 68:1994;3-7.
31. Malinen T., Palotie A., Pakkala S., Peltonen L., Ruutu T., Jansson S.E. Acceleration of chronic myeloid leukemia correlates with calcitonin gene hypermethylation. Blood. 77:1991;2435-2440.
32. INK4B gene deletions in primary leukemias. Blood. 86:1995;311-315.
33. Sharpless N.E., DePinho R.A. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev. 9:1999;22-30.
34. Pomerantz J., Schreiber-Agus N., Liegeois N.J.et al. The INK4a tumor-suppressor gene product, p19ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 92:1998;713-723.
35. Lee W.I., Kantarjian H., Glassman A., Talpaz M., Lee M.S. Quantitative measurement of BCR/abl transcripts using real-time polymerase chain reaction. Ann Oncol. 13:2002;781-788.
36. ARF locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer. 89:2000;1976-1982.
37. INK4B deletions in childhood T-cell acute lymphoblastic leukaemia. Br J Haematol. 112:2001;680-690.